METHOD FOR DETERMINING NUCLEAR LENS DENSITY Russian patent published in 2014 - IPC G01N33/48 

FIELD: medicine.

SUBSTANCE: patient's venous blood serum is analysed for vascular endothelial growth factor (VEGF). If the derived values in the patients suffering type 1 diabetes mellitus is 141-187 pg/ml, degree 1 and very low nuclear lens density are diagnosed; the value of 188-234 pg/ml enables diagnosing degree 2 and low nuclear lens density; and the value of 235-280 pg/ml shows degree 3 and moderate nuclear lens density. In the patients suffering type 2 diabetes mellitus, the VEGF value of 281-330 pg/ml provides diagnosing degree 2 and low nuclear lens density; the derived value of 331-382 pg/ml shows degree 3 and moderate nuclear lens density; if the value is 383-432 pg/ml, degree 4 and high nuclear lens density are diagnosed; the respective value of 433-478 pg/ml provides diagnosing degree 5 and very high nuclear lens density. In the patients diagnosed with no diabetes mellitus, the VEGF value of 290-336 pg/ml ensures diagnosing degree 2 and low nuclear lens density; the value of 337-379 pg/ml provides degree 3 and moderate nuclear lens density; if the value is 380-426 pg/ml, degree 4 and high nuclear lens density are diagnosed; the derived value of 427-465 pg/ml provides diagnosing degree 5 and very high nuclear lens density.

EFFECT: invention provides performing a phacoemulsification using the sparing ultrasound parameters that minimises its impact on the eyeball tissues and reduces a risk of the related postoperative complications in the patients suffering diabetes mellitus.

2 tbl, 2 ex